en.Wedoany.com Reported - U.S. startup Serif Biomedicines has recently emerged from stealth mode, introducing a novel therapeutic class called "modified DNA." Founded by Flagship Pioneering in 2021 and headquartered in Cambridge, Massachusetts, the company currently has about 50 employees. On April 21, Flagship Pioneering announced an initial committed investment of $50 million in Serif to develop its artificial intelligence-assisted platform and advance its first drug discovery programs.

Dr. Jacob Rubens, co-founder and CEO of Serif, stated that modified DNA combines the scalability and repeat-dosing capability of mRNA with the durability and programmability of gene therapy, while mitigating the limitations of both. The technology alters the structure and chemical form of DNA to reduce innate immunogenicity and enables DNA transcribed into therapeutic RNA and proteins after delivery to the cell nucleus. The company has demonstrated that modified DNA is well-tolerated in non-human primates and can achieve durable gene expression in preclinical models.

Serif’s initial drug discovery programs focus on rare diseases and immune programming, with specific details expected to be announced later this year. Rubens emphasized that modified DNA, as a universal information molecule, has broad potential applications. The company plans to present more data at scientific meetings to validate its efficacy and safety.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com